Medication Tables

Drug name Indication Half-life (T1/2), Notable side effects (associate Dosing
Target symptoms: state if positive metabolism to pathway or NT)
or negative effect (CYP 450
Potency (if noted. receptor enzyme)
occupancy if noted )
Neurotransmitter(s) affected
Typical antipsychotics (conventional) non selectively blocks D2 receptors in histamine affect pathway
Haloperidol Targets: positive symptoms 18-24 hours Extrapyramidal symptoms
(Haldol) Potency: High CYP2D6 and (EPS) (nigrostriatal), sedation
Neurotransmitter affected: D2 CYP3A4 (histamine affect), weight gain
antagonist (histamine affect), tardive
Dosing: PM1-10 mg/day, max 100 dyskinesia (nigrostriatal),
mg/day hyperprolactinemia
IM 5-10 mg every 4-8 hours (tuberofundibular)
Thioridazine Targets: positive symptoms 24 hours Sedation (histamine affect),
Potency: Low CYP2D6 dry mouth (anticholinergic
Neurotransmitter affected: D2 effect), blurred vision
antagonist, 5HT2A (anticholinergic effect), QT
prolongation (asstd with K+
ion channels), EPS
(nigrostriatal)
Thiothixene Targets: positive symptoms 6-24 hours Sedation (histamine affect),
(Navene) Potency: Medium CYP2D6 dry mouth (anticholinergic
Neurotransmitter affected: D2 effect), blurred vision
antagonist (anticholinergic effect), EPS
(nigrostriatal)
Fluphenazine Targets: positive symptoms 15-30 hours EPS (nigrostriatal), sedation
(prolixin) Potency: Medium CYP2D6 and (histamine affect), weight gain
Neurotransmitter affected: D2 CYP3A4 (histamine affect), tardive
antagonist, D3, 5HT7, 1- dyskinesia(nigrostriatal)
adrenergic

Mesoridazine Targets: positive symptoms 10-20 hours Sedation (histamine affect),
Potency: Low CYP2D6 dry mouth (anticholinergic
Neurotransmitter affected: D2 effect), weight gain (histamine
antagonist affect), EPS (nigrostriatal)

Chlorpromazin Targets: positive symptoms 30-50 hours QTc prolongation (asstd with
e (Thorazine) Potency: Low CYP2D6 and K+ ion channels), EPS